Conservest Capital Advisors, Inc. Clovis Oncology, Inc. Transaction History

Conservest Capital Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 10, 2019	SELL	$12.81 - $25.67 $106,527 - $213,471	-8,316 Closed	0 $0
Q1 2019 Apr 08, 2019	SELL	$17.66 - $30.28 $178,648 - $306,312	-10,116 Reduced 54.88%	8,316 $206,000
Q2 2018 Jul 09, 2018	BUY	$42.06 - $62.4 $275,577 - $408,844	6,552 Added 55.15%	18,432 $838,000
Q3 2017 Oct 12, 2017	BUY	$67.17 - $84.81 $797,979 - $1.01 Million	11,880	11,880 $979,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Conservest Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Conservest Capital Advisors, Inc. with notifications on news.